Misetionamide for Platinum-Resistant Ovarian Cancer
This study is testing a new drug called misetionamide (also known as GP-2250) for women with ovarian cancer that has returned or grown after platinum-based chemotherapy (platinum-resistant ovarian cancer). The main goals are to find a safe and tolerable dose of misetionamide and see how well it works. You might be able to join if you are over 18, have platinum-resistant ovarian cancer, and have had up to two previous treatments. The study is currently enrolling patients into Part 2, which focuses on misetionamide alone.
- Study design
- This is a Phase 1 study with an estimated 80 participants. Part 2 uses a 3+3 dose escalation design, meaning groups of three participants will receive increasing doses of misetionamide.
- What's involved
- You would continue treatment until your disease progresses, you experience unacceptable side effects, or you choose to stop.
- Compensation
- Not stated in the trial record.
- Follow-up
- Not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine
At a glance
Conditions
Where it's being run
4 sites across 4 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety, tolerance and recommended misetionamide dose for subsequent studies in PROC
Evaluation of Adverse Events (AEs), Serious AEs (SAEs), physical exam, vital signs, ECG, ECOG score, clinical labs.